Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy
NCT03734952Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- May 2023
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Overall Survival at 5 years. Started May 2023; status: recruiting.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03734952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03734952.